Drug Trial Radar · NCT06877858
MethaLoad Dose-Finding Study
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 25, 2025
Primary completion
Dec 31, 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Ashish P Thakrar, MD MSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Methadone is an effective treatment for opioid use disorder (OUD), but starting it has become harder now that most people with OUD use fentanyl. Methadone is usually started at a low dose and increased slowly over several weeks. For people who use fentanyl, these low early doses might not relieve withdrawal and cravings, and many people stop treatment before reaching a dose that works. This study will test whether starting methadone with a higher first-day dose (a "loading dose") is safe and comfortable for people who use fentanyl. It will also help find the best loading dose to test in future, larger studies. We will enroll 24 adults with OUD who use fentanyl. Participants will start methadone while staying on an inpatient research unit, where staff will monitor them closely. Each person will get either the usual starting dose or one of four loading doses, assigned by chance. Participants and the staff who rate their symptoms will not know which dose was given. As the study goes on, the research team will use safety results from earlier participants to decide which loading doses later participants receive.
Conditions
- Opioid Use Disorder (OUD)
Interventions
Methadone hydrochlorideDrug
Methadone loading dose initiation (vs. standard initiation in the TAU arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) rateTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn Center for Studies of Addiction (CSA)
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.